The road to resistance: EGFR mutation and cetuximab

Alberto Bardelli, Pasi A. Jänne

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

Original languageEnglish
Pages (from-to)199-200
Number of pages2
JournalNature Medicine
Volume18
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Epidermal Growth Factor Receptor
Mutation
Colorectal Neoplasms
Antibodies
Therapeutics
Cetuximab

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

The road to resistance : EGFR mutation and cetuximab. / Bardelli, Alberto; Jänne, Pasi A.

In: Nature Medicine, Vol. 18, No. 2, 02.2012, p. 199-200.

Research output: Contribution to journalArticle

Bardelli, Alberto ; Jänne, Pasi A. / The road to resistance : EGFR mutation and cetuximab. In: Nature Medicine. 2012 ; Vol. 18, No. 2. pp. 199-200.
@article{6d592c4155a4416daeef01c80dd96bac,
title = "The road to resistance: EGFR mutation and cetuximab",
abstract = "Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).",
author = "Alberto Bardelli and J{\"a}nne, {Pasi A.}",
year = "2012",
month = "2",
doi = "10.1038/nm.2646",
language = "English",
volume = "18",
pages = "199--200",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The road to resistance

T2 - EGFR mutation and cetuximab

AU - Bardelli, Alberto

AU - Jänne, Pasi A.

PY - 2012/2

Y1 - 2012/2

N2 - Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

AB - Some individuals with colorectal cancer benefit from therapies targeting the epidermal growth factor receptor (EGFR). However, resistance to EGFR blockade inevitably occurs. The characterization of a new mechanism of resistance to the EGFR-specific antibody cetuximab provides clues into how therapeutic strategies might be designed to overcome this specific resistance mechanism (pages 221-223).

UR - http://www.scopus.com/inward/record.url?scp=84856721608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856721608&partnerID=8YFLogxK

U2 - 10.1038/nm.2646

DO - 10.1038/nm.2646

M3 - Article

C2 - 22310681

AN - SCOPUS:84856721608

VL - 18

SP - 199

EP - 200

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -